Page last updated: 2024-10-19

niacin and Hemorrhage

niacin has been researched along with Hemorrhage in 13 studies

Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.

Hemorrhage: Bleeding or escape of blood from a vessel.

Research Excerpts

ExcerptRelevanceReference
" However, the trial also identified previously unrecognized serious adverse effects (including new-onset diabetes, bleeding, and infection)."2.90Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial. ( Armitage, J; Chen, F; Haynes, R; Hopewell, JC; Landray, MJ; Li, J; Parish, S; Valdes-Marquez, E, 2019)
"Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3."2.79Effects of extended-release niacin with laropiprant in high-risk patients. ( Armitage, J; Aung, T; Collins, R; Craig, M; Haynes, R; Hopewell, JC; Jiang, L; Landray, MJ; Parish, S; Tomson, J; Wallendszus, K, 2014)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19909 (69.23)18.7374
1990's0 (0.00)18.2507
2000's1 (7.69)29.6817
2010's3 (23.08)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Haynes, R2
Valdes-Marquez, E1
Hopewell, JC2
Chen, F1
Li, J1
Parish, S2
Landray, MJ2
Armitage, J2
Aung, T1
Tomson, J1
Wallendszus, K1
Craig, M1
Jiang, L1
Collins, R1
McCarthy, M1
PELUSE, S1
LEVENSON, SM1
GREEN, RW1
BIANCO, T1
VOARINO, EL1
STURA, L1
MANNARI, M1
KRASSER, R1
PLETSCHER, A1
GORDON, DM1
PEPLAU, G1
Chaidemenos, GC1
Mourellou, O1
Karakatsanis, G1
Koussidou, T1
Xenidis, E1
Charalampidou, H1
Avgoloupis, D1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Trial of the Long-term Clinical Effects of Raising HDL Cholesterol With Extended Release Niacin/Laropiprant[NCT00461630]Phase 325,673 participants (Actual)Interventional2007-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Coronary or Non-coronary Revascularisation

(NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)

Interventionparticipants (Number)
ER Niacin/Laropiprant807
Placebo897

Major Coronary Events

Non-fatal myocardial infarction (MI) or coronary death (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)

Interventionparticipants (Number)
ER Niacin/Laropiprant668
Placebo694

Major Vascular Event

Non-fatal myocardial infarction or coronary death, non-fatal or fatal stroke, or revascularisation (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)

Interventionparticipants (Number)
ER Niacin/Laropiprant1696
Placebo1758

Mortality

All-cause mortality (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)

Interventionparticipants (Number)
ER Niacin/Laropiprant798
Placebo732

Stroke

Fatal or non-fatal (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)

Interventionparticipants (Number)
ER Niacin/Laropiprant498
Placebo499

Trials

2 trials available for niacin and Hemorrhage

ArticleYear
Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.
    Clinical therapeutics, 2019, Volume: 41, Issue:9

    Topics: Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus; Double-Blind Method; Drug T

2019
Effects of extended-release niacin with laropiprant in high-risk patients.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Aged; Atherosclerosis; Cholesterol, LDL; Delayed-Action Preparations; Diabetes Mellitus; Double-Blin

2014

Other Studies

11 other studies available for niacin and Hemorrhage

ArticleYear
Niacin fails to reduce vascular events in large randomised trial.
    BMJ (Clinical research ed.), 2014, Jul-22, Volume: 349

    Topics: Blood Glucose; Cholesterol, HDL; Delayed-Action Preparations; Diabetes Mellitus; Drug Therapy, Combi

2014
Gingival hemorrhage with oral manifestations in hereditary hemorrhagic telangiectasia; successful control with sclerosing agent sylnasol; effect of vitamin P and nicotinic acid; role in case reported which was observed 5 years.
    Archives of otolaryngology, 1946, Volume: 44, Issue:6

    Topics: Flavones; Gingiva; Gingival Hemorrhage; Hemorrhage; Humans; Mouth; Niacin; Nicotinic Acids; Oral Hem

1946
Ascorbic acid, riboflavin, thiamin, and nicotinic acid in relation to severe injury, hemorrhage, and infection in the human.
    Annals of surgery, 1946, Volume: 124

    Topics: Ascorbic Acid; Deficiency Diseases; Hemorrhage; Humans; Infections; Metabolism; Niacin; Nicotinic Ac

1946
[Isonicotinic acid hydrazide and hemorrhages in tuberculosis].
    Minerva medica, 1953, Mar-24, Volume: 44, Issue:24

    Topics: Hemorrhage; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary

1953
[Vascular effects of isonicotinic acid hydrazide; case reports].
    Minerva ginecologica, 1954, Mar-31, Volume: 6, Issue:6

    Topics: Female; Hemorrhage; Humans; Isoniazid; Niacin; Nicotinic Acids; Pelvis; Tuberculosis; Tuberculosis,

1954
[The effect of nicotinic acid isomers on bleeding and coagulation time].
    Beitrage zur Klinik der Tuberkulose und spezifischen Tuberkulose-Forschung, 1954, Volume: 112, Issue:3

    Topics: Blood Coagulation; Blood Coagulation Tests; Capillary Permeability; Collapse Therapy; Hemorrhage; Hu

1954
[Effect of isopropyl-isonicotinic acid hydrazide on the metabolism of catechol amines and 5-hydroxytryptamine in the brain].
    Schweizerische medizinische Wochenschrift, 1957, Dec-14, Volume: 87, Issue:50

    Topics: Amines; Brain; Catechols; Epinephrine; Hemorrhage; Isoniazid; Niacin; Nicotinic Acids; Norepinephrin

1957
SUDDEN LOSS OF VISION; DIAGNOSIS AND MANAGEMENT.
    Medical times, 1964, Volume: 92

    Topics: Adrenal Cortex Hormones; Angiomatosis; Anticoagulants; Aortic Diseases; Blindness; Carbonic Anhydras

1964
[Case report on the injurious side-effects of isoniazid].
    Zentralblatt fur Chirurgie, 1954, Volume: 79, Issue:43

    Topics: Gastrointestinal Hemorrhage; Hemorrhage; Isoniazid; Niacin; Nicotinic Acids; Stomach; Stomach Diseas

1954
[Ultrasonics in ophthalmology].
    Annales d'oculistique, 1951, Volume: 184, Issue:8

    Topics: Eye Diseases; Hemorrhage; Humans; Ophthalmology; Pellagra; Ultrasonic Therapy; Ultrasonics; Vitreous

1951
Acute hemorrhagic pellagra in an Albanian refugee.
    Cutis, 2002, Volume: 69, Issue:2

    Topics: Acute Disease; Adult; Albania; Facial Dermatoses; Follow-Up Studies; Hand Dermatoses; Hemorrhage; Hu

2002